SCHEMBL2145017

SCHEMBL2145017

CS(=O)(=O)N1CCCC1Cn1cc(-c2ncnc3[nH]ccc23)cn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 18/20 0.51
JAK1 P23458 12/20 0.51
HDAC6 Q9UBN7 7/20 0.48
HDAC1 Q13547 5/20 0.48
JAK3 P52333 6/20 0.47
TYK2 P29597 3/20 0.47
HDAC3 O15379 1/20 0.47
HDAC7 Q8WUI4 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC10 Q969S8 1/20 0.47
HDAC11 Q96DB2 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC5 Q9UQL6 1/20 0.47
NCOR2 Q9Y618 1/20 0.47
RET P07949 3/20 0.46
ROCK1 Q13464 3/20 0.46
CIT O14578 2/20 0.46
GAK O14976 2/20 0.46
ROCK2 O75116 2/20 0.46
ULK1 O75385 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2438934 1.00 JAK2 (0.51) JAK2JAK1HDAC6HDAC1JAK3
SCHEMBL18605109 0.83 AURKA (0.51) JAK2JAK1JAK3TYK2IKBKB
SCHEMBL10315626 0.79 JAK2 (0.59) JAK2JAK1HDAC6HDAC1JAK3
SCHEMBL101195 0.76 JAK2 (0.62) JAK2JAK1HDAC6HDAC1JAK3
SCHEMBL98901 0.75 JAK2 (0.52) JAK2JAK1HDAC6HDAC1JAK3
SCHEMBL2144875 0.75 JAK2 (0.52) JAK2JAK1HDAC6HDAC1JAK3
SCHEMBL12799122 0.75 JAK2 (0.54) JAK2JAK1HDAC6HDAC1JAK3
SCHEMBL12799123 0.75 JAK2 (0.54) JAK2JAK1HDAC6HDAC1JAK3
SCHEMBL28466379 0.74 JAK2 (0.66) JAK2JAK1JAK3
SCHEMBL13774665 0.74 JAK2 (0.61) JAK2JAK1HDAC6HDAC1JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2348023-B9 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors INCYTE HOLDINGS CORP (US) 2017-03-08 EP claimed
EP-2343299-B9 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors INCYTE HOLDINGS CORP (US) 2017-03-08 EP claimed
EP-2343299-B1 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors INCYTE CORP (US) 2015-11-04 EP claimed
EP-2348023-B1 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors INCYTE CORP (US) 2015-05-06 EP claimed
US-8415362-B2 Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors INCYTE CORPORATION (US) 2013-04-09 US claimed
EP-1966202-B1 HETEROARYL SUBSTITUTED PYRROLO[2,3-B]PYRIDINES AND PYRROLO[2,3-B]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORP (US) 2011-09-21 EP claimed
EP-2348023-A1 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors Incyte Corporation (US) 2011-07-27 EP claimed
EP-2343299-A1 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors Incyte Corporation (US) 2011-07-13 EP claimed